HCV Lecture

32
م ي ح ر ل ا ن م ح ر ل ه ا ل ل م ا س ب م ي ح ر ل ا ن م ح ر ل ه ا ل ل م ا س ب

Transcript of HCV Lecture

Page 1: HCV Lecture

الرحيم الرحمن الله الرحيم بسم الرحمن الله بسم

Page 2: HCV Lecture

Chronic Hepatitis C Chronic Hepatitis C

Dr : Dr : Walid El - Walid El - SherbinySherbiny

Tropical Medicine Tropical Medicine Mansoura UniversityMansoura University

Page 3: HCV Lecture

Incidence

Hepatitis C infect 200 million people worldwide HCV is a major Epidemic problem in Egypt. Many data suggest that the Overall incidence in Egypt is 15% of population. The highest prevalence in Northern Delta 28% The lowest prevalence in Cairo and Alexandria 9% and 6 % respectively.

Page 4: HCV Lecture

Virology

Single stranded, enveloped RNA virus.There are 6 genotypes: 1 in USA . 2,3 in Europe& 4 in Egypt

Genotypes 2 &3 has the best response to Interferon Therapy

Genotypes 1 & 4 has the least response to interferon therapy

Page 5: HCV Lecture

Pathology

Ranges from minimal periportal lymphocytic inflammation to active hepatitis with bridging fibrosis, hepatocyte necrosis and frank cirrhosis.

Activity / Fibrosis score Steatosis, lymphoid aggregates and bile duct damage are frequently found in the liver biopsy in patient with HCV infection

Page 6: HCV Lecture

Methods Of Transmission

1-Iatrogenic medical and dental procedure (most important) 2-Injection drug use 3-Blood transfusion and organ transplantation 4-Occupational exposure to blood (Medical and paramedical) 5-Sexual and perinatal exposure (probably low)

- The campaign of treatment of Bilharziasis using Tartar Emetics with same needle used for all patients Play an important role in transmission of HCV

- Bad sterilization procedures in hospitals is very important source of infection

Page 7: HCV Lecture

Clinical Manifestations

Chronic hepatitis C means HCV infection for more than 6 months.

Usually asymptomatic, accidentally discovered but it may be presented with Fatigue, weight loss, muscle pain, intermittent low grade fever and flu like symptoms or GIT symptoms.

Hepatitis C (PCR) is detectable in the blood within 1 to 3 weeks after infection, and antibodies to the virus within 3 to 12 weeks (up to 1 y).

Page 8: HCV Lecture

Extra-hepatic manifestationsPathogenesis a- Mediators of autoimmunity b- Immune complex formation c- Virus invasion and replication

Includes: 1- Strongly associated

1-Mixed cryoglobulinemia 2-Membrenoproliferative glomerulonephritis 3-Porphyria cutenea tarda 4-Sjogren syndrome 5-Lymphoproliferative disorders 6-Leukocytoclastic vasculitis 7-Neuropathy

Page 9: HCV Lecture

2- Possibly associated2- Possibly associated

1-Lichen planus1-Lichen planus 2-Autoimmune thrombocytopenia2-Autoimmune thrombocytopenia 3-Thyroid disease3-Thyroid disease 4-Type 2 diabetes4-Type 2 diabetes 5-Corneal ulcers (Mooren ulcers)5-Corneal ulcers (Mooren ulcers) 6-Pulmonary fibrosis6-Pulmonary fibrosis 7-Systemic vasculitis (polyarteritis 7-Systemic vasculitis (polyarteritis

nodosa nodosa 8-Arthralgia, myalgia, polyarthritis 8-Arthralgia, myalgia, polyarthritis

Page 10: HCV Lecture

VasculitisVasculitis

Page 11: HCV Lecture

VetiligoVetiligo

Page 12: HCV Lecture

PsoriasisPsoriasis

Page 13: HCV Lecture

PsoriasisPsoriasis

Page 14: HCV Lecture

Pyoderma Gangrenosum (early Pyoderma Gangrenosum (early lesion with necrotic centre)lesion with necrotic centre)

Page 15: HCV Lecture

Pyoderma Pyoderma GangrenosumGangrenosum

Page 16: HCV Lecture

Pyoderma Pyoderma GangrenosumGangrenosum

Page 17: HCV Lecture

Systemic Lupus ErythematosusSystemic Lupus Erythematosus

Page 18: HCV Lecture

Sjogren’s SyndromeSjogren’s Syndrome

Page 19: HCV Lecture

Idiopathic pulmonary fibrosis

Page 20: HCV Lecture

Prevention

1-Avoid sharing drug needles 2-Avoid unsanitary tattooing, Acupuncture and body piercing 3-Avoid needle stick injury, sharing personal items such as razors, nail clippers and teeth brush

4-Use latex condoms correctly in those with multiple sexual partners

5-Screening of blood & blood products for viral markers

6-Strilization

No vaccine available to protect against contracting HCV

Page 21: HCV Lecture

Treatment

Standard treatment is a combination of Pegylated Interferon and Ribavirin.

All patients with measurable level of HCV RNA and liver biopsy shows bridging fibrosis along with at least with moderate inflammation and necrosis should be considered potential candidate for therapy.

In the absence of contraindications, treatment is recommended because patients are at risk of developing liver cirrhosis and Hepatocellular carcinoma

Page 22: HCV Lecture

Investigations before INF

1-Anti HCV antibody & HB markers 2-CBC 3-Liver function tests 4-Quantitaive PCR 5-Pregnancy test 6-Serum T.S.H 7-Serum alfa feto protein 8-Autoimmune markers 9-IHA for Bilharziasis 10-Random blood sugar and creatinine 11-ECG 12-Fundus Examination 13-Abdominal U/S 14-Liver Biopsy 15-Upper GIT endoscopy (in patients with portal hypertension)

Page 23: HCV Lecture

Pegylated Interferon

Attachment of polyethylene glycol to a protein

(pegylation) reduces its rate Of absorption following

subcutaneous injection, reduces renal clearance and

decrease immunogenicity of protein with resulting

increasing in half life of interferon.

Page 24: HCV Lecture

Duration of Therapy

Differs according to genotype.

For Genotypes 2 & 3 require 24 weeks of Peg INF. alfa + ribavirin 800 mg/d while Genotypes 1 & 4 require 48 weeks of INF alfa + ribavirin 1000-1200 mg/d.

Failure to decrease the viral load by 2 Logs after 12 w. of treatment is highly predictive of failure of treatment in naïve patient who has genotype 1

Page 25: HCV Lecture

Time to Do PCR

-Basal PCR (before start of treatment)-After 4 weeks (Quantitative), if responder (Super response)-After 12 weeks (Quantitative): If responder (early

virologic response) then continue, if Non responder stop

-After 24 w. (Qualitative), if Non responder stop.

-After 48 weeks (Qualitative, if responder it is end treatment response.-SVR (sustained virologic response): –ve Qualitative PCR 6 months after end treatment

Page 26: HCV Lecture

Predictor of Non response To HCV treatment:

1-Infection with Genotype 1 2-High viral load (800,000 IU/ml)3-Advanced fibrosis stage 5 or cirrhosis stage 64-High body mass index5-age more than 40 years6-African American race7-Coinfection HIV with HCV

Page 27: HCV Lecture

Absolute contraindications to hepatitis C therapy

- Active psychiatric illnesses, such as major depression, schizophrenia, or bipolar disorder that is not controlled - Having undergone renal, heart, or lung transplant

- autoimmune hepatitis

- Untreated hyperthyroidism

- Pregnancy OR Breast feeding

Page 28: HCV Lecture

Severe concurrent disease: Severe concurrent disease:

severe uncontrolled hypertension, heart severe uncontrolled hypertension, heart failure, failure, considerable coronary artery considerable coronary artery disease, poorly disease, poorly controlled diabetes controlled diabetes mellitus, severe chronic mellitus, severe chronic obstructive obstructive pulmonary disease pulmonary disease

Known hypersensitivity to INF or RibavirinKnown hypersensitivity to INF or Ribavirin

Inability to practice birth controlInability to practice birth control

Relative contraindications:Relative contraindications:

a- a- pancytopeniapancytopenia

b- b- Seizure disordersSeizure disorders

Page 29: HCV Lecture

Adverse effects of Hepatitis c therapy:

1-Flu like symptoms2-Neutropenia and

Thrombocytopenia3-Depression and Psychosis4-HTN and Diabetes5- thyroid6-fall of hair7-With Ribavirin, the most

prominent side effect is heamolysis while the most serious is teratogenicity

Page 30: HCV Lecture

Two forms of contraceptions must be used during therapy and for 6 months following treatment cessation.

Anemia associated with IFN/RBV therapy is treated by Epotein alfa once weekly S.C. with OR without reduction of Ribavirin dose

Leucopenia is treated with granulocyte stimulating factor s.c.

Page 31: HCV Lecture

Experimental treatment:

1-Viramidine is a prodrug of the Ribavirin that has better targeting of the liver (Phase 3 trials). It will be used in conjunction with interferon as an alternative to Ribavirin

2-Protease inhibitors (VX 950) Known as Telaprevir is currently in Phase 3 trials

Page 32: HCV Lecture